Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 26, 2010. The report discloses a specific corporate action regarding a notifiable share interest in JCR Pharmaceuticals Co., Limited, a Japanese pharmaceutical company listed on the Osaka Stock Exchange.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for GSK. The only financial data disclosed relates to the specific transaction with JCR Pharmaceuticals:
- Transaction Date: March 26, 2010
- Shares Acquired: 1,560,000 Common shares
- Exercise Price: JPY 650 per share
- Post-Transaction Ownership: 16.73% of outstanding Common shares
- Voting Rights: 16.92% of total voting rights
Material Changes
As a result of the transaction, GSK's ownership stake in JCR Pharmaceuticals increased from 12.05% to 16.73%. This acquisition established GSK as the largest shareholder of JCR Pharmaceuticals. The holding is maintained through GSK's wholly owned subsidiary, Glaxo Group Limited.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the disclosure of the share acquisition. No unusual items were reported in this document.
Key Facts for Investor Verification
- Verify the total cost of the acquisition (1,560,000 shares at JPY 650) and its impact on GSK's consolidated balance sheet.
- Confirm the strategic rationale for increasing the stake in JCR Pharmaceuticals to become the largest shareholder.
- Review the announcement issued by JCR to the Osaka Stock Exchange on March 26, 2010, for additional transaction details.
- Assess whether this 16.73% stake triggers any specific regulatory reporting requirements or governance changes in Japan.